John Maraganore

Advisor, Venture Partner

John joined Omega Funds in September 2022. He is based in Boston and is assisting Omega in several company creation efforts currently ongoing. John is currently a Board member of Omega portfolio company Aerium Therapeutics.

John Maraganore served as the founding CEO and a Director of Alnylam from 2002 to 2021, where he built and led the company from early platform research on RNA interference through global approval and commercialization of the first four RNAi therapeutic medicines, ONPATTRO®, GIVLAARI®, OXLUMO® and Leqvio®. At Alnylam, he also led the company’s value creation strategy, building over $25 billion in market capitalization and forming over 20 major pharmaceutical alliances. He continues to serve on the Alnylam Scientific Advisory Board.

Prior to Alnylam, Dr. Maraganore was at Millennium Pharmaceuticals, Inc., where he was responsible for the company’s product franchises in oncology, and cardiovascular, inflammatory and metabolic diseases, in addition to leadership of M&A, strategy and biotherapeutics functions. Before Millennium, he held scientific and business roles at Biogen, Inc., where he invented and led the discovery and development of ANGIOMAX® (bivalirudin) for injection. Previously, he was a scientist at ZymoGenetics, Inc. and the Upjohn Company.

John currently holds positions with several other investment firms and is also a member of the Board of Directors of several publicly traded companies. John received his MS and PhD in biochemistry and molecular biology at the University of Chicago.